Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2016

Open Access 01-12-2016 | Research

Molecular epidemiology of hepatitis C infections in Ningxia, China: genotype, phylogeny and mutation analysis

Authors: Zhonglan Wu, Lijia Cui, Weiming Zhao, Dongzhi Yang, Hui Chen, Ruiqing Wang, Xuemin Wang, Linqi Zhang, Tianhua He

Published in: Virology Journal | Issue 1/2016

Login to get access

Abstract

Background

Current prevalence and genotype distribution of hepatitis C virus (HCV) infection remain unknown in Ningxia, northwest China.

Methods

From June to December 2013, 13,022 individuals were screened in Ningxia HIV/AIDS Sentinel Surveillance System, with their demographic features collected and serum samples tested for HCV antibody. Sero-positive drug users were further subjected to sequencing of NS5B and Core regions of HCV.

Results

The anti-HCV prevalence was 0.34 % among individuals without history of drug use, while it was 15.80 % among drug users. Of 79 NS5B sequences amplified from drug users, 64 (81.0 %) were male and 51 (64.0 %) were injection drug users (IDUs). Subtype 3a (40.5 %) and 1b (25.3 %) were the most predominant subtypes, followed in frequency by 3b (10.1 %) and 2a (7.6 %). Subtype distribution has no significant difference between injection and non-injection drug users. Based on phylogeographic analysis, HCV strains in Ningxia IDUs were mainly originated from two sites, Yunnan province (in southwest China bordering Myanmar, also known as Burma) and Xinjiang Autonomous Region (in northwest China on the border of Central Asia), which are the two major drug trafficking originates in China. Previously reported drug-resistance mutations were also scanned in this treatment-naïve population. Amino acid substitutions (C316N) associated with direct anti-viral agents (DAA) resistance were identified in the NS5B region in seven samples.

Conclusion

This study is the first to reveal the existence of multiple genotypes of HCV in Ningxia, an inland province in northwest China, suggesting the rapid spreading of the virus.
Appendix
Available only for authorised users
Literature
1.
Chen YS, Li L, Cui FQ, Xing WG, Wang L, Jia ZY, Zhou MG, Gong XH, Wang FZ, Zheng H, et al. A sero-epidemiological study on hepatitis C in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2011;32:888–91.PubMed
2.
3.
Peng J, Lu Y, Liu W, Zhu Y, Yan X, Xu J, Wang X, Wang Y, Liu W, Sun Z. Genotype distribution and molecular epidemiology of hepatitis C virus in Hubei, Central China. PLoS One. 2015;10:e0137059.CrossRefPubMedPubMedCentral
4.
Wang J, Liu J, Huang Y, Wright DJ, Li J, Zhou Z, He W, Yang T, Yao F, Zhu X, et al. The persistence of hepatitis C virus transmission risk in China despite serologic screening of blood donations. Transfusion. 2013;53:2489–97.CrossRefPubMed
5.
Rao H, Wei L, Lopez-Talavera JC, Shang J, Chen H, Li J, Xie Q, Gao Z, Wang L, Wei J, et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2014;29:545–53.CrossRefPubMedPubMedCentral
6.
Yuan JM, Govindarajan S, Henderson BE, Yu MC. Low prevalence of hepatitis C infection in hepatocellular carcinoma (HCC) cases and population controls in Guangxi, a hyperendemic region for HCC in the People's Republic of China. Br J Cancer. 1996;74:491–3.CrossRefPubMedPubMedCentral
7.
Zhang F, Zhu H, Wu Y, Dou Z, Zhang Y, Kleinman N, Bulterys M, Wu Z, Ma Y, Zhao D, et al. HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China National Free Antiretroviral Treatment Program, 2010–12: a retrospective observational cohort study. Lancet Infect Dis. 2014;14:1065–72.CrossRefPubMed
8.
Bao YP, Liu ZM. Systematic review of HIV and HCV infection among drug users in China. Int J STD AIDS. 2009;20:399–405.CrossRefPubMed
9.
Garten RJ, Lai S, Zhang J, Liu W, Chen J, Vlahov D, Yu XF. Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. Int J Epidemiol. 2004;33:182–8.CrossRefPubMed
10.
Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:S45–57.CrossRefPubMed
11.
Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol. 2013;28 Suppl 1:7–10.CrossRefPubMed
12.
Su YY, Liu HX, Wang N. Hepatitis C virus genotypes in China: a systematic review. Zhonghua Liu Xing Bing Xue Za Zhi. 2013;34:80–4.PubMed
13.
National Bureau of Statistics of China.: Communiqué of the National Bureau of Statistics of People's Republic of China on Major Figures of the 2010 Population Census [1] (No. 2). 29 April 2011.
14.
Leslie D. Islam in traditional China: a short history to 1800. Canberra: Canberra College of Advanced Education; 1986.
15.
Chen X, He JM, Ding LS, Zhang GQ, Zou XB, Zheng J. Prevalence of hepatitis B virus and hepatitis C virus in patients with human immunodeficiency virus infection in Central China. Arch Virol. 2013;158:1889–94.CrossRefPubMed
16.
Ministry of Health of China (MOH), National Center for AIDS Prevention and Control (NCAIDS) and Collaboration Group for National HIV Sentinel Surveillance Program. Set up of national sentinel surveillance of HIV infection in China and its report in 1995. Zhongguo Xing Bing Ai Zi Bing Fang Zhi. 1996;2:193–7.
17.
Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol. 2007;24:1596–9.CrossRefPubMed
18.
Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22:4673–80.CrossRefPubMedPubMedCentral
19.
Lu L, Wang M, Xia W, Tian L, Xu R, Li C, Wang J, Rong X, Xiong H, Huang K, et al. Migration patterns of hepatitis C virus in China characterized for five major subtypes based on samples from 411 volunteer blood donors from 17 provinces and municipalities. J Virol. 2014;88:7120–9.CrossRefPubMedPubMedCentral
20.
Gill MS, Lemey P, Faria NR, Rambaut A, Shapiro B, Suchard MA. Improving Bayesian population dynamics inference: a coalescent-based model for multiple loci. Mol Biol Evol. 2013;30:713–24.CrossRefPubMed
21.
Purdy MA, Forbi JC, Sue A, Layden JE, Switzer WM, Opare-Sem OK, Phillips RO, Khudyakov YE. A re-evaluation of the origin of hepatitis C virus genotype 2 in West Africa. J Gen Virol. 2015;96:2157–64.CrossRefPubMedPubMedCentral
22.
23.
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74.CrossRefPubMed
24.
25.
Tokita H, Okamoto H, Luengrojanakul P, Vareesangthip K, Chainuvati T, Iizuka H, Tsuda F, Miyakawa Y, Mayumi M. Hepatitis C virus variants from Thailand classifiable into five novel genotypes in the sixth (6b), seventh (7c, 7d) and ninth (9b, 9c) major genetic groups. J Gen Virol. 1995;76(Pt 9):2329–35.CrossRefPubMed
26.
Touzet S, Kraemer L, Colin C, Pradat P, Lanoir D, Bailly F, Coppola RC, Sauleda S, Thursz MR, Tillmann H, et al. Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative Research). Eur J Gastroenterol Hepatol. 2000;12:667–78.CrossRefPubMed
27.
Franco S, Casadella M, Noguera-Julian M, Clotet B, Tural C, Paredes R, Martinez MA. No detection of the NS5B S282T mutation in treatment-naive genotype 1 HCV/HIV-1 coinfected patients using deep sequencing. J Clin Virol. 2013;58:726–9.CrossRefPubMed
28.
Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, Lee B, Heckerman D, Carlson J, Reyor LL, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology. 2008;48:1769–78.CrossRefPubMedPubMedCentral
29.
Lu J, Zhou Y, Lin X, Jiang Y, Tian R, Zhang Y, Wu J, Zhang F, Zhang Y, Wang Y, Bi S. General epidemiological parameters of viral hepatitis A, B, C, and E in six regions of China: a cross-sectional study in 2007. PLoS One. 2009;4:e8467.CrossRefPubMedPubMedCentral
30.
Xia X, Luo J, Bai J, Yu R. Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis. Public Health. 2008;122:990–1003.CrossRefPubMed
31.
Zhao SM, Jiang TL, Gao FX, Lu L, Zheng HQ, Hu J, Fan YH, Li B, Xiao RR, Yury K. Analysis of true voluntary blood donors with anti-HCV prevalence and implications for donor management in Chongqing, China. Transfus Med. 2007;17:210–1.CrossRefPubMed
32.
Tian D, Li L, Liu Y, Li H, Xu X, Li J. Different HCV genotype distributions of HIV-infected individuals in Henan and Guangxi, China. PLoS One. 2012;7:e50343.CrossRefPubMedPubMedCentral
33.
Zhang YY, Lok AS, Chan DT, Widell A. Greater diversity of hepatitis C virus genotypes found in Hong Kong than in mainland China. J Clin Microbiol. 1995;33:2931–4.PubMedPubMedCentral
34.
Ye Y, Yan YS, Chen G, Yan PP, Zheng WX, Deng YQ, Yang XH, Wu SL, Zhang ZS. Molecular epidemiology of hepatitis C virus among different groups of people in the province of Fujian, China. Arch Virol. 2013;158:611–8.CrossRefPubMed
35.
Xia X, Lu L, Tee KK, Zhao W, Wu J, Yu J, Li X, Lin Y, Mukhtar MM, Hagedorn CH, Takebe Y. The unique HCV genotype distribution and the discovery of a novel subtype 6u among IDUs co-infected with HIV-1 in Yunnan, China. J Med Virol. 2008;80:1142–52.CrossRefPubMedPubMedCentral
36.
Zhang C, Wu N, Liu J, Ge Q, Huang Y, Ren Q, Feng Q, He G. HCV subtype characterization among injection drug users: implication for a crucial role of Zhenjiang in HCV transmission in China. PLoS One. 2011;6:e16817.CrossRefPubMedPubMedCentral
37.
Yan Z, Fan K, Wang Y, Fan Y, Tan Z, Deng G. Changing pattern of clinical epidemiology on hepatitis C virus infection in Southwest China. Hepat Mon. 2012;12:196–204.CrossRefPubMedPubMedCentral
38.
Thong VD, Akkarathamrongsin S, Poovorawan K, Tangkijvanich P, Poovorawan Y. Hepatitis C virus genotype 6: virology, epidemiology, genetic variation and clinical implication. World J Gastroenterol. 2014;20:2927–40.CrossRefPubMedPubMedCentral
39.
40.
Zhuang X, Wang Y, Chow EP, Liang Y, Wilson DP, Zhang L. Risk factors associated with HIV/HCV infection among entrants in methadone maintenance treatment clinics in China: a systematic review and meta-analysis. Drug Alcohol Depend. 2012;126:286–95.CrossRefPubMed
41.
Goncalves Rossi LM, Escobar-Gutierrez A, Rahal P. Multiregion deep sequencing of hepatitis C virus: An improved approach for genetic relatedness studies. Infect Genet Evol. 2016;38:138–45.CrossRefPubMed
42.
Applegate TL, Gaudieri S, Plauzolles A, Chopra A, Grebely J, Lucas M, Hellard M, Luciani F, Dore GJ, Matthews GV. Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C. Antivir Ther. 2015;20:199–208.CrossRefPubMed
43.
Poveda E, Wyles DL, Mena A, Pedreira JD, Castro-Iglesias A, Cachay E. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res. 2014;108:181–91.CrossRefPubMed
44.
Ji H, Kozak RA, Biondi MJ, Pilon R, Vallee D, Liang BB, La D, Kim J, Van Domselaar G, Leonard L, et al. Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations. Virology. 2015;477:1–9.CrossRefPubMed
45.
Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology. 2010;138:447–62.CrossRefPubMed
46.
Trevino A, de Mendoza C, Parra P, Rodriguez C, Madejon A, Plaza Z, del Romero J, Poveda E, Soriano V. Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients. Antivir Ther. 2011;16:413–6.CrossRefPubMed
47.
Ali S, Leveque V, Le Pogam S, Ma H, Philipp F, Inocencio N, Smith M, Alker A, Kang H, Najera I, et al. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob Agents Chemother. 2008;52:4356–69.CrossRefPubMedPubMedCentral
48.
Zhang L, Yap L, Xun Z, Wu Z, Wilson DP. Needle and syringe programs in Yunnan, China yield health and financial return. BMC Public Health. 2011;11:250.CrossRefPubMedPubMedCentral
49.
Jarlais DD. Systematic review research on needle/syringe programs and opiate substitution programs in low- and middle-income countries. J Food Drug Anal. 2013;21:S59–61.CrossRefPubMedPubMedCentral
50.
National Center for AIDS/STD Control and Prevention. Chinese CDC. In: Ningxia AIDS/HCV sentinel surveliance system 2015 report (Unpublshished). 2015.
51.
State Council of P.R. China. China’s action plan for reducing and preventing the spread of HIV/AIDS (2006–2010). 2006.
52.
May MT, Justice AC, Birnie K, Ingle SM, Smit C, Smith C, Neau D, Guiguet M, Schwarze-Zander C, Moreno S, et al. Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration. J Acquir Immune Defic Syndr. 2015;69:348–54.CrossRefPubMedPubMedCentral
53.
Sidique N, Kohli A, Shivakumar B, Migueles S, Subramanian GM, Naggie S, Polis MA, Masur H, Kottilil S. HIV/HCV-coinfected natural viral suppressors have better virologic responses to PEG-IFN and ribavirin than ARV-treated HIV/HCV patients. J Acquir Immune Defic Syndr. 2011;58:e38–40.CrossRefPubMedPubMedCentral
54.
Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, Sun Y, Xuan SY. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53:726–36.CrossRefPubMed
55.
Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med. 2013;158:807–20.CrossRefPubMed
56.
Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, SS M, Torriani FJ, Dieterich DT, Thomas DL. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–25.CrossRefPubMed
Metadata
Title
Molecular epidemiology of hepatitis C infections in Ningxia, China: genotype, phylogeny and mutation analysis
Authors
Zhonglan Wu
Lijia Cui
Weiming Zhao
Dongzhi Yang
Hui Chen
Ruiqing Wang
Xuemin Wang
Linqi Zhang
Tianhua He
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2016
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-016-0635-y

Other articles of this Issue 1/2016

Virology Journal 1/2016 Go to the issue

Research

Serologic and genotypic characterization of hepatitis B virus in HIV-1 infected patients from South West and Littoral Regions of Cameroon

Research

Pre-immune state induced by chicken interferon gamma inhibits the replication of H1N1 human and H9N2 avian influenza viruses in chicken embryo fibroblasts

Research

Increased CD56bright NK cells in HIV-HCV co-infection and HCV mono-infection are associated with distinctive alterations of their phenotype

Methodology

Development of an isothermoal amplification-based assay for rapid visual detection of an Orf virus

Research

Human cytomegalovirus reactivation from latency: validation of a “switch” model in vitro

Research

Detection of Malawi polyomavirus sequences in secondary lymphoid tissues from Italian healthy children: a transient site of infection

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits